Meeting
2020 Genitourinary Cancers Symposium
Safety of BXCL701, a small molecule inhibitor of dipeptidyl peptidases (DPP), with pembrolizumab, (pembro, anti-PD-1) monoclonal antibody, in men with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Rahul Raj Aggarwal
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Rahul Raj Aggarwal , Dan Costin , Vincent J. O'Neill , Cedric R Burg , Diane I. Healey , Johann S. De Bono , Jingsong Zhang , Eric Jay Small
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03910660
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 140)
Abstract #
140
Poster Bd #
F20
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma phenotype—Phase 2a results.
First Author: Jingsong Zhang
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC).
First Author: Scott T. Tagawa
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
DNA vaccine with pembrolizumab to elicit antitumor responses in patients with metastatic, castration-resistant prostate cancer (mCRPC).
First Author: Douglas G. McNeel
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY).
First Author: Yu-Wei Chen